264 related articles for article (PubMed ID: 33243800)
1. Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in
de Maar JS; Suelmann BBM; Braat MNGJA; van Diest PJ; Vaessen HHB; Witkamp AJ; Linn SC; Moonen CTW; van der Wall E; Deckers R
BMJ Open; 2020 Nov; 10(11):e040162. PubMed ID: 33243800
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Lyon PC; Griffiths LF; Lee J; Chung D; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
J Ther Ultrasound; 2017; 5():28. PubMed ID: 29118984
[TBL] [Abstract][Full Text] [Related]
3. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.
Mikhail AS; Negussie AH; Pritchard WF; Haemmerich D; Woods D; Bakhutashvili I; Esparza-Trujillo J; Brancato SJ; Karanian J; Agarwal PK; Wood BJ
Int J Hyperthermia; 2017 Nov; 33(7):733-740. PubMed ID: 28540814
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermia-mediated doxorubicin release from thermosensitive liposomes using MR-HIFU: therapeutic effect in rabbit Vx2 tumours.
Staruch RM; Hynynen K; Chopra R
Int J Hyperthermia; 2015 Mar; 31(2):118-33. PubMed ID: 25582131
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Spiers L; Gray M; Lyon P; Sivakumar S; Bekkali N; Scott S; Collins L; Carlisle R; Wu F; Middleton M; Coussios C
BMC Cancer; 2023 Sep; 23(1):896. PubMed ID: 37741968
[TBL] [Abstract][Full Text] [Related]
6. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC; Gray MD; Mannaris C; Folkes LK; Stratford M; Campo L; Chung DYF; Scott S; Anderson M; Goldin R; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
Lancet Oncol; 2018 Aug; 19(8):1027-1039. PubMed ID: 30001990
[TBL] [Abstract][Full Text] [Related]
7. The effect of injected dose on localized tumor accumulation and cardiac uptake of doxorubicin in a Vx2 rabbit tumor model using MR-HIFU mild hyperthermia and thermosensitive liposomes.
Cheng B; Bing C; Staruch RM; Shaikh S; Wodzak Staruch M; Szczepanski D; Williams NS; Laetsch TW; Chopra R
Int J Hyperthermia; 2020; 37(1):1052-1059. PubMed ID: 32892667
[TBL] [Abstract][Full Text] [Related]
8. Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin.
Bing C; Patel P; Staruch RM; Shaikh S; Nofiele J; Wodzak Staruch M; Szczepanski D; Williams NS; Laetsch T; Chopra R
Int J Hyperthermia; 2019; 36(1):196-203. PubMed ID: 30541350
[TBL] [Abstract][Full Text] [Related]
9. Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery.
Borys N; Dewhirst MW
Adv Drug Deliv Rev; 2021 Nov; 178():113985. PubMed ID: 34555486
[TBL] [Abstract][Full Text] [Related]
10. Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice.
Aloss K; Bokhari SMZ; Leroy Viana PH; Giunashvili N; Schvarcz CA; Szénási G; Bócsi D; Koós Z; Storm G; Miklós Z; Benyó Z; Hamar P
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542073
[TBL] [Abstract][Full Text] [Related]
11. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.
Zagar TM; Vujaskovic Z; Formenti S; Rugo H; Muggia F; O'Connor B; Myerson R; Stauffer P; Hsu IC; Diederich C; Straube W; Boss MK; Boico A; Craciunescu O; Maccarini P; Needham D; Borys N; Blackwell KL; Dewhirst MW
Int J Hyperthermia; 2014 Aug; 30(5):285-94. PubMed ID: 25144817
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin.
de Smet M; Hijnen NM; Langereis S; Elevelt A; Heijman E; Dubois L; Lambin P; Grüll H
Invest Radiol; 2013 Jun; 48(6):395-405. PubMed ID: 23399809
[TBL] [Abstract][Full Text] [Related]
13. Interleaved Mapping of Temperature and Longitudinal Relaxation Rate to Monitor Drug Delivery During Magnetic Resonance-Guided High-Intensity Focused Ultrasound-Induced Hyperthermia.
Kneepkens E; Heijman E; Keupp J; Weiss S; Nicolay K; Grüll H
Invest Radiol; 2017 Oct; 52(10):620-630. PubMed ID: 28598900
[TBL] [Abstract][Full Text] [Related]
14. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
[No Abstract] [Full Text] [Related]
15. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
16. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermia-induced doxorubicin delivery from thermosensitive liposomes via MR-HIFU in a pig model.
Sebeke LC; Castillo Gómez JD; Heijman E; Rademann P; Simon AC; Ekdawi S; Vlachakis S; Toker D; Mink BL; Schubert-Quecke C; Yeo SY; Schmidt P; Lucas C; Brodesser S; Hossann M; Lindner LH; Grüll H
J Control Release; 2022 Mar; 343():798-812. PubMed ID: 35134460
[TBL] [Abstract][Full Text] [Related]
18. Large-Volume Hyperthermia for Safe and Cost-Effective Targeted Drug Delivery Using a Clinical Ultrasound-Guided Focused Ultrasound Device.
Lyon PC; Mannaris C; Gray M; Carlisle R; Gleeson FV; Cranston D; Wu F; Coussios CC
Ultrasound Med Biol; 2021 Apr; 47(4):982-997. PubMed ID: 33451816
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.
Farr N; Wang YN; D'Andrea S; Starr F; Partanen A; Gravelle KM; McCune JS; Risler LJ; Whang SG; Chang A; Hingorani SR; Lee D; Hwang JH
Int J Hyperthermia; 2018 May; 34(3):284-291. PubMed ID: 28715967
[TBL] [Abstract][Full Text] [Related]
20. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center.
Yang W; Lee JC; Chen MH; Zhang ZY; Bai XM; Yin SS; Cao K; Wang S; Wu W; Yan K
J Cancer Res Ther; 2019; 15(4):773-783. PubMed ID: 31436231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
